Open Access[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma
Author(s) -
José AntonRodriguez,
Daniel Lewis,
Ibrahim Djoukhadar,
David R. Russell,
P. J. Julyan,
David Coope,
Andrew T. King,
Simon Lloyd,
D. Gareth Evans,
Alan Jackson,
Julian C. Matthews
Publication year - 2019
Publication title -
otology and neurotology
Language(s) - English
Resource type - Journals
eISSN - 1537-4505
pISSN - 1531-7129
DOI - 10.1097/mao.0000000000002272
Subject(s) - medicine , nuclear medicine , fluorodeoxyglucose , standardized uptake value , positron emission tomography , neurofibromatosis , receiver operating characteristic , schwannoma , positron emission , radiology
To investigate whether [F]fluorothymidine (FLT) and/or [F]fluorodeoxyglucose (FDG) positron emission tomography (PET) can differentiate growth in neurofibromatosis 2 (NF2) related vestibular schwannomas (VS) and to evaluate the importance of PET scanner spatial resolution on measured tumor uptake.